B-intervention	0	10	Vandetanib
I-intervention	11	15	with
I-intervention	16	25	docetaxel
O	26	28	as
O	29	35	second
O	35	36	-
O	36	40	line
O	41	50	treatment
O	51	54	for
O	55	63	advanced
O	64	70	breast
O	71	77	cancer
O	77	78	:
O	79	80	a
O	81	87	double
O	87	88	-
O	88	93	blind
O	93	94	,
O	95	102	placebo
O	102	103	-
O	103	113	controlled
O	113	114	,
O	115	125	randomized
O	126	131	Phase
O	132	134	II
O	135	140	study
O	140	141	.

O	142	145	The
O	146	149	aim
O	150	152	of
O	153	157	this
O	158	163	Phase
O	164	166	II
O	167	172	study
O	173	176	was
O	177	179	to
O	180	186	assess
O	187	190	the
O	191	199	efficacy
O	200	203	and
O	204	210	safety
O	211	213	of
O	214	224	vandetanib
O	225	227	in
O	228	239	combination
O	240	244	with
O	245	254	docetaxel
O	255	257	in
B-eligibility	258	266	patients
I-eligibility	267	271	with
I-eligibility	272	282	pretreated
I-eligibility	283	291	advanced
I-eligibility	292	298	breast
I-eligibility	299	305	cancer
O	305	306	.

O	307	310	The
O	311	318	primary
O	319	324	study
O	325	334	objective
O	335	338	was
O	339	341	to
O	342	349	compare
O	350	353	the
B-outcome-Measure	354	360	number
I-outcome-Measure	361	363	of
I-outcome-Measure	364	375	progression
I-outcome-Measure	376	382	events
O	383	385	in
O	386	394	patients
O	395	404	receiving
O	405	409	once
O	409	410	-
O	410	415	daily
O	416	420	oral
O	421	431	vandetanib
O	432	433	(
O	433	436	100
O	437	439	mg
O	439	440	)
O	441	443	in
O	444	455	combination
O	456	460	with
O	461	470	docetaxel
O	471	472	(
O	472	475	100
O	476	478	mg
O	478	479	/
O	479	480	m
O	480	481	(
O	481	482	2
O	482	483	)
O	484	486	iv
O	487	492	every
O	493	495	21
O	496	500	days
O	500	501	)
O	502	508	versus
B-control	509	516	placebo
I-control	517	521	plus
I-control	522	531	docetaxel
O	531	532	.

B-total-participants	533	538	Sixty
I-total-participants	538	539	-
I-total-participants	539	543	four
O	544	552	patients
O	553	557	were
O	558	568	randomized
O	569	571	to
O	572	579	receive
O	580	585	study
O	586	595	treatment
O	596	597	(
O	597	598	n
O	599	600	=
B-intervention-participants	601	603	35
O	603	604	,
O	605	615	vandetanib
O	615	616	;
O	617	618	n
O	619	620	=
B-control-participants	621	623	29
O	623	624	,
O	625	632	placebo
O	632	633	)
O	633	634	.

O	635	636	A
O	637	645	slightly
O	646	653	greater
O	654	660	number
O	661	663	of
O	664	672	patients
O	673	676	had
O	677	688	experienced
O	689	690	a
B-outcome	691	702	progression
I-outcome	703	708	event
O	709	711	by
O	712	715	the
O	716	720	data
O	721	724	cut
O	724	725	-
O	725	728	off
O	729	731	in
O	732	735	the
O	736	746	vandetanib
O	747	752	group
O	753	754	(
B-iv-bin-abs	754	756	24
O	757	758	[
B-iv-bin-percent	758	760	69
I-iv-bin-percent	760	761	%
O	761	762	]
O	762	763	)
O	764	772	compared
O	773	777	with
O	778	781	the
O	782	789	placebo
O	790	795	group
O	796	797	(
B-cv-bin-abs	797	799	18
O	800	801	[
B-cv-bin-percent	801	803	62
I-cv-bin-percent	803	804	%
O	804	805	]
O	805	806	)
O	806	807	;
O	808	810	HR
O	811	812	=
O	813	814	1
O	814	815	.
O	815	817	19
O	817	818	,
O	819	822	two
O	822	823	-
O	823	828	sided
O	829	831	80
O	831	832	%
O	833	835	CI
O	835	836	:
O	837	838	0
O	838	839	.
O	839	841	79
O	841	842	-
O	842	843	1
O	843	844	.
O	844	846	81
O	846	847	;
O	848	851	two
O	851	852	-
O	852	857	sided
O	858	859	P
O	860	861	=
O	862	863	0
O	863	864	.
O	864	866	59
O	866	867	)
O	867	868	,
O	869	879	suggesting
O	880	884	that
O	885	888	the
O	889	897	addition
O	898	900	of
O	901	911	vandetanib
O	912	914	to
O	915	924	docetaxel
O	925	928	did
O	929	932	not
O	933	939	affect
O	940	943	the
O	944	948	risk
O	949	951	of
O	952	959	disease
O	960	971	progression
O	972	980	compared
O	981	985	with
O	986	993	placebo
O	994	998	plus
O	999	1008	docetaxel
O	1008	1009	.

O	1010	1013	The
B-outcome	1014	1020	safety
I-outcome	1021	1024	and
I-outcome	1025	1037	tolerability
I-outcome	1038	1045	profile
O	1046	1048	of
O	1049	1052	the
O	1053	1064	combination
O	1065	1072	therapy
O	1073	1082	reflected
O	1083	1088	those
O	1089	1091	of
O	1092	1096	both
O	1097	1102	drugs
O	1103	1105	as
O	1106	1117	monotherapy
O	1118	1124	agents
O	1124	1125	.

O	1126	1128	In
O	1129	1137	patients
O	1138	1142	with
O	1143	1151	advanced
O	1152	1158	breast
O	1159	1165	cancer
O	1165	1166	,
O	1167	1177	vandetanib
O	1178	1182	plus
O	1183	1192	docetaxel
O	1193	1196	was
O	1197	1206	generally
B-outcome	1207	1211	well
I-outcome	1212	1221	tolerated
O	1221	1222	.

B-outcome	1223	1231	Clinical
I-outcome	1232	1239	benefit
O	1240	1243	was
O	1244	1247	not
O	1248	1257	different
O	1258	1260	to
O	1261	1265	that
O	1266	1274	observed
O	1275	1279	with
O	1280	1287	placebo
O	1288	1292	plus
O	1293	1302	docetaxel
O	1302	1303	.

O	1304	1311	However
O	1311	1312	,
O	1313	1316	due
O	1317	1319	to
O	1320	1323	the
O	1324	1329	small
O	1330	1337	patient
O	1338	1344	number
O	1345	1347	it
O	1348	1351	was
O	1352	1355	not
O	1356	1364	possible
O	1365	1367	to
O	1368	1373	yield
O	1374	1380	robust
O	1381	1388	results
O	1388	1389	,
O	1390	1397	further
O	1398	1406	research
O	1407	1409	is
O	1410	1418	required
O	1419	1421	to
O	1422	1430	identify
O	1431	1441	predictive
O	1442	1449	factors
O	1450	1453	for
O	1454	1461	patient
O	1462	1471	selection
O	1471	1472	.
